Understanding treatment and outcomes for chronic Hepatitis B infection
Study on the Antiviral Therapy and Prognosis of Patients With Chronic HBV Infection
This study is testing how well different antiviral treatments work for people with chronic Hepatitis B to see which ones help them the most.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 79 Years |
| Sex | All |
| Sponsor | Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT05392387 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with chronic Hepatitis B virus (HBV) infection, aiming to evaluate the effectiveness of different antiviral therapies, including pegylated interferon and nucleos(t)ide analogues. Participants will be divided into groups based on their treatment regimen, and their clinical features, serum HBV DNA levels, and other biochemical markers will be monitored over time. The study seeks to identify factors that influence therapeutic efficacy and patient prognosis, contributing to the global goal of eliminating hepatitis B as a public health threat by 2030.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with confirmed chronic HBV infection.
Not a fit: Patients with chronic liver injury caused by factors other than HBV, such as autoimmune diseases or substance abuse, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment strategies for chronic HBV infection, leading to improved patient outcomes and potentially reducing mortality rates.
How similar studies have performed: Other studies have shown promise in evaluating antiviral therapies for HBV, but this specific cohort approach may provide novel insights into treatment efficacy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: patients with evidence of chronic HBV infection Exclusion Criteria: chronic liver injury mainly caused by other reasons, such as autoimmune diseases, alcohol, drugs and so on.
Where this trial is running
Changsha, Hunan
- Department of Infectious Disease, Xiangya Hospital, Central South University — Changsha, Hunan, China (Recruiting)
Study contacts
- Study coordinator: Yan Huang
- Email: ganrankedrhyan@163.com
- Phone: +86 13874854142
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.